Combination treatment for older adults with lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of medications for adults aged 60 and older with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The goal is to see if this treatment can help control the cancer and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You have been diagnosed with diffuse large B-cell lymphoma (DLBCL).
- You have at least one tumor that can be measured or seen on scans.
- You have not had chemotherapy or radiation for this lymphoma before.
- You are expected to live at least 3 more months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug combination (azacitidine plus standard chemotherapy) for people with a certain genetic subtype of diffuse large B-cell lymphoma (DLBCL) that has a mutation in the TP53 gene. It may offer a more targeted treatment option.
This trial tests a new combination of drugs for a type of lymphoma that is harder to treat. The goal is to improve outcomes for patients aged 65 and older who have this specific genetic feature.
This trial tests a new combination of targeted therapies and chemotherapy for older adults with a diagnosis of diffuse large B-cell lymphoma. The goal is to see if this approach is safe and effective for people who may not be able to tolerate standard treatment.
This study tests a new combination of drugs for people with diffuse large B-cell lymphoma (a type of blood cancer) that has come back or not responded to previous treatment. The combination includes an experimental drug (EZH2i), an immunotherapy (glofitamab), and chemotherapy (GemOx), all given together to see if it is safe and effective.
This study tests a combination of three drugs (polatuzumab vedotin, rituximab, and chidamide) for older adults newly diagnosed with a certain type of aggressive lymphoma called double-expressor DLBCL. The goal is to see if this combination is safe and effective for people who may not be able to handle standard, more intense chemotherapy.
This trial tests a new combination of drugs for people with a type of lymphoma called diffuse large B cell lymphoma, especially if you are older or not healthy enough for standard full-dose chemotherapy. The treatment includes two immunotherapy drugs (epcoritamab and polatuzumab) plus a reduced-intensity chemotherapy regimen (mini-CHP). The goal is to see if this combination is safe and effective for people who may not tolerate stronger treatments.
Hear when a new DLBCL - Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.